Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report

While amyloid-targeting therapies continue to predominate in the Alzheimer’s disease (AD) drug development pipeline, there is increasing recognition that to effectively treat the disease it may be necessary to target other mechanisms and pathways as well. In December 2019, The EU/US CTAD Task Force...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauthier, Serge, Aisen, P. S., Cummings, J., Detke, M. J., Longo, F. M., Raman, R., Sabbagh, M., Schneider, L., Tanzi, R., Tariot, P., Weiner, M., Touchon, J., Vellas, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
CTAD Task Force Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223540/
https://www.ncbi.nlm.nih.gov/pubmed/32420298
http://dx.doi.org/10.14283/jpad.2020.18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223540/
https://www.ncbi.nlm.nih.gov/pubmed/32420298
http://dx.doi.org/10.14283/jpad.2020.18

Ejemplares similares